CN101123888B - 寡糖混合物 - Google Patents
寡糖混合物 Download PDFInfo
- Publication number
- CN101123888B CN101123888B CN200680005467.9A CN200680005467A CN101123888B CN 101123888 B CN101123888 B CN 101123888B CN 200680005467 A CN200680005467 A CN 200680005467A CN 101123888 B CN101123888 B CN 101123888B
- Authority
- CN
- China
- Prior art keywords
- lactose
- oligosaccharides
- oligosaccharide
- oligosaccharide mixture
- newborn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 139
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 135
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 59
- 210000000481 breast Anatomy 0.000 claims abstract description 33
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 79
- 239000008101 lactose Substances 0.000 claims description 79
- 239000000463 material Substances 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 34
- 235000013350 formula milk Nutrition 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 24
- 108010046377 Whey Proteins Proteins 0.000 claims description 18
- 102000007544 Whey Proteins Human genes 0.000 claims description 18
- 239000005862 Whey Substances 0.000 claims description 16
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 16
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 238000001228 spectrum Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 9
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 7
- 239000012466 permeate Substances 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 240000006439 Aspergillus oryzae Species 0.000 claims description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 235000008452 baby food Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 235000020246 buffalo milk Nutrition 0.000 claims description 2
- 235000020251 goat milk Nutrition 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 235000020256 human milk Nutrition 0.000 description 11
- 210000004251 human milk Anatomy 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 description 9
- 235000013406 prebiotics Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 241000736262 Microbiota Species 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000406668 Loxodonta cyclotis Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 108010058314 rennet Proteins 0.000 description 2
- 229940108461 rennet Drugs 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- -1 nitrogen-containing compound Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000020209 toddler milk formula Nutrition 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
- A23C9/1206—Lactose hydrolysing enzymes, e.g. lactase, beta-galactosidase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及来源于动物乳的寡糖混合物、包含所述寡糖混合物的食品和用于生产所述寡糖混合物的方法。
Description
发明领域
本发明涉及来源于动物乳的寡糖混合物、包含所述寡糖混合物的食品和用于生产所述寡糖混合物的方法。
发明背景
人类的大肠被多种细菌所建群,所述细菌对消化道生理具有正面和负面的双重作用,也具有其它系统性的影响。结肠中所发现的细菌的优势类群包括类菌体、双歧杆菌、真细菌、梭菌和乳杆菌。所存在的细菌响应结肠中的底物可用性、氧化还原电位、pH、O2压和分布,具有波动的活性。通常,肠内的细菌可分为对宿主发挥潜在危害或有益作用的种类。致病作用(例如,其可能由梭菌或类菌体引起)包括腹泻、感染、肝脏损害、致癌作用和肠腐烂。健康促进作用可以由有害细菌的生长抑制、免疫功能的刺激、增强必需营养成分的消化和吸收及维生素的合成所引起。具有健康促进作用的细菌类群(例如双歧杆菌和乳杆菌)在数量和活性上的增加是值得期望的。
特别就婴儿来说,直至出生前,婴儿的胃肠道被认为是无菌的。在出生的过程中,其遭遇了来自母亲消化道和皮肤的细菌并开始变得被建群。对应于婴儿的喂养,消化道小型生物群的组成存在大的不同。母乳喂养的婴儿的粪便菌群包括双歧杆菌和一些乳杆菌种类的可观群体,而配方喂养的婴儿具有更复杂的小型生物群,双歧杆菌、类菌体、梭菌和链球菌通常都存在。断乳后,类似成人模式的消化道小型生物群模式得以建立。
对于所有婴儿均建议使用母乳。然而,在一些情况下,母乳喂养是不充分的,或者由于医学原因是不成功的,或者母亲并不选择母乳喂养。针对这些情况,已开发了婴儿配方。
向食品中添加益生元是促进结肠中有益细菌的数量和/或活性增长的一种方法。益生元是不易消化的食品成分,其通过选择性地刺激结肠中一种或有限数量的细菌的生长和/或活性来有益地影响宿主,从而增进宿主健康。此类成分是不易消化的,因为其在胃或小肠中不能被分解和吸收,从而完整地通过并到达结肠,在此处由有益细菌选择性地进行发酵。益生元的例子包括某些寡糖,例如果寡糖(FOS)和半乳寡糖(GOS)。
已知人乳比大多数其它动物乳含有更大量的不能消化的寡糖。事实上,不能消化的寡糖代表着母乳中第三大固体成分(在乳糖和脂类之后),初乳中以12-15g/l的浓度存在,成熟乳汁中以5-8g/l存在。人乳寡糖对于酶水解是非常有抵抗力的,表明这些寡糖可显示出与其热值并不直接相关的基本功能。
由于人乳的组成已有更好的了解,也已建议将益生元添加至婴儿配方中。补充了益生元的多种婴儿配方例如果寡糖和半乳寡糖混合物的多种婴儿配方可通过商业途径获得。然而,此类混合物只是粗略地近似人乳中寡糖的混合物。人乳中已检测到超过100种不同的寡糖成分,其中一些至今根本未在动物乳例如牛奶中检测到,或者仅检测到少量。仅以非常小的量在牛奶和初乳中存在或根本不存在的人乳寡糖种类的例子有唾液酸化和岩藻糖基化的寡糖。
美国专利申请号2003/0129278描述了以产生于一种或几种动物乳的寡糖为基础的寡糖混合物,其特征在于其包含至少两种寡糖级分,每一级分均由至少两种不同的寡糖组成,游离的乳糖不属于所述寡糖。存在于寡糖混合物中的寡糖全谱不同于在动物乳或从中提取寡糖级分的动物乳中所存在的那些寡糖。此外a)如果所述仅寡糖提取于一种动物乳,中性寡糖与酸性(唾液酸化)寡糖的比率为96-60:10-40重量%,或b)如果所述寡糖提取于至少两种动物乳,从两种不同动物乳中所提取的寡糖每种占寡糖混合物中所存在的寡糖总量的10重量%。
美国专利号5,270,462描述了从干酪乳清或粗制凝乳酶乳清以高浓度回收唾液酸结合的寡糖、唾液酸结合的肽和唾液酸结合的脂类的方法,其包括如下步骤:调整干酪乳清或粗制凝乳酶乳清至pH2-5;将乳清与阳离子交换剂相接触以产生通过交换剂的溶液;并将所述通过交换剂的溶液浓缩和/或脱盐。所得的具有高含量唾液酸的组合物可用作食品材料或医学材料。
EP0458358涉及生产含有按重量计10-15%的半乳寡糖的脱脂奶粉的方法,其包括:
(i)浓缩脱脂乳以获得具有按重量计20-50%的固体含量的浓缩乳,
(ii)向浓缩乳中加入β-半乳糖苷酶,以产生酶促反应,
(iii)加热所获得的反应混合物30秒钟至15分钟,至70-85℃的温度,以便终止酶促反应,并
(iv)喷雾干燥反应终止的混合物。
本发明的目标是提供寡糖混合物,其作为益生元是有效的,特别是在人类消化道中是有效的,并且其具有比那些果寡糖和半乳寡糖混合物所提供的寡糖谱更加接近于人乳寡糖谱的寡糖谱。
发明概述
在一方面,本发明涉及来自动物乳的寡糖混合物,其中混合物具有小于250的乳糖:寡糖比例,且含有与其所来源的乳相同的寡糖谱。此成分是新的保护性和免疫调节成分,例如,与可获得的益生元成分例如果寡糖和半乳寡糖相比,其结构上更接近于人母乳寡糖,例如因为具有更高比例的唾液酸化的寡糖。低乳糖:寡糖比例具有下述优势,即可将寡糖混合物加入婴儿配方和其它食品中,也不会导致非自然的高含量乳糖。例如,可将0.5至50g寡糖混合物加入每升配方奶粉中。优选地,混合物具有125至1.25的乳糖:寡糖比例。
优选地,寡糖混合物来自一种或多种奶牛奶、山羊奶或水牛奶,尽管来自其它动物例如绵羊、骆驼、马和大象的奶也可使用。
任选地寡糖混合物进一步包含β-半乳-寡糖(β-GOS)。人乳比其它动物乳例如奶牛奶含有显著更多的中性寡糖,因此,提高本发明寡糖混合物中的GOS含量从而生产具有更加接近于人乳寡糖谱的混合物是所希望的。本发明混合物中的寡糖:β-半乳-寡糖比例可在0.01至99的范围内。优选地,OS:GOS比例在1:2至1:20之间,特别优选的比例在1:2至1:6之间。
在本发明的另一方面涉及包含如上所述的寡糖混合物的食品。任选地食品为婴儿食品或配方,但该产品可为任何由小孩、婴儿或成人使用的食物或饮料。含有寡糖混合物作为益生元的食品的消耗将选择性地促进结肠中一种或有限数量的细菌的生长和/或活性,从而增进宿主健康。
在本发明更进一步的方面中提供了用于生产寡糖混合物的方法,所述寡糖混合物来自动物乳并具有与其所来源的乳相同的寡糖谱,该方法包括下述步骤(a)将去蛋白质的乳材料浓缩至50-75%总固体量,(b)将浓缩的乳材料进行乳糖去除步骤以产生具有小于250的乳糖:寡糖比例的液体,且(c)将乳材料脱矿质,脱矿质步骤在浓缩步骤之前或者乳糖去除步骤之后进行。
优选地,方法的步骤(b)包括在浓缩步骤之后的乳糖结晶步骤,以除去乳糖晶体并产生具有小于250的乳糖:寡糖比例的液体。
备选地,乳糖去除步骤可包括将步骤a)中产生的浓缩材料进行喷雾干燥,然后加水溶解寡糖,而使乳糖处于结晶形式。
任选地,可重复(在其中一些乳糖已通过结晶去除的情况中)或增加(在其中使用了差别溶解度的情况中)乳糖结晶和去除步骤,以便进一步浓缩液体和除去乳糖。
优选地,脱矿质步骤在乳糖去除步骤之后进行。
优选地,去蛋白质的乳材料是乳或乳清的超滤渗透物。然而,任何去蛋白质的乳材料例如酸乳清或甜乳清(均为干酪制造的副产品)在乳清蛋白质去除之后均可用于每种情况中。
任选地,方法进一步包括用β-半乳糖苷酶处理以生产β-半乳-寡糖。所使用的β-半乳糖苷酶可为任何微生物、植物或动物来源,条件是它显示出重要的转半乳糖苷活性。优选地,所使用的β-半乳糖苷酶来源于米曲霉(Aspergillusoryzae)。该酶处理可在去蛋白质的乳材料浓缩之前或乳糖去除步骤完成之后,或者如希望在去蛋白质的乳材料浓缩之前和乳糖去除步骤完成之后发生,但是优选地发生在乳糖去除步骤完成之后。
在乳糖去除步骤之后,液体产品可用单独的蛋白酶和/或其组合进行处理,以将任何残留的乳蛋白质和肽降解为分子量减小的实体。这是特别优选的,如果将寡糖混合物掺入低变应原性婴儿配方中,该配方是为具有发生牛奶过敏反应危险的婴儿设计的,且因此仅含有部分水解的蛋白质。
所获得的液体产品可以液体形式使用,但优选地将其喷雾干燥以产生粉末。
发明详述
本发明提供了来自动物乳的寡糖混合物及其生产方法,其中混合物具有小于250的乳糖:寡糖比例,并含有与其所来源的乳相同的寡糖谱。该混合物可掺入婴儿或成人食品中并赋予益生、免疫调节和保护的效果。
此处将寡糖定义为那些在动物乳中天然发现的并具有3至20(包括3和20)范围之内的聚合度(DP)的寡糖。
本发明的寡糖混合物也含有乳糖(DP=2),且具有小于250,优选地在125至1.25之间的乳糖:寡糖比例。与最初的动物乳相比,这相当于在寡糖混合物中降低了2至200倍的乳糖含量,其等于寡糖与乳糖之间的比例增加2至200倍。
本发明的寡糖混合物来自于一种或多种动物乳。该乳可从任何一种动物获得,特别是从奶牛、山羊、水牛、马、大象、骆驼或绵羊中获得。
用于生产寡糖混合物的方法中的原料是去蛋白质的乳材料,例如已除去蛋白质的乳、或者已从中去除乳清蛋白质的乳清或任何制备的或改良的乳清材料。此类材料包括酸乳清和甜乳清。优选的原料是乳超滤渗透物和乳清超滤渗透物。备选地,原料可为重构的粉末,例如粉末状超滤渗透物。
原料应为去蛋白质的产品,因为浓缩过程中蛋白质的存在可导致不希望的美拉反应和褐变。可通过任何已知的方式对原料进行去蛋白质,例如酸沉淀、加热方法、离子交换。然而,优选地,通过超滤来实现蛋白质的去除,这还从原料中去除了脂类。
也可通过任何已知的方式,例如反渗透、纳膜过滤或离子交换对原料脱矿质。备选地,脱矿质步骤可在乳糖去除步骤之后再次利用任何已知的方式来进行。
原料的pH可在3至7.5之间,尽管优选5至6范围内的pH以阻止寡糖水解例如唾液酸乳糖的脱唾液酸化,并帮助减少褐变反应。
将去蛋白质的乳材料通过任何已知的方式浓缩至50-75%总固体(TS),优选地55-60%TS,条件是温度不升高至将寡糖水解或脱唾液酸的水平。优选地在50-90℃、更优选地50-75℃的温度下进行浓缩。蒸发是一种优选的技术,其在80-200mbar的压力下进行。在此方法中,温度不升至60℃以上,以保证寡糖不受影响。备选地,如果原料是粉末,可通过粉末的适当重构来实现浓缩至所期望的水平。
此方法任选地包括进一步用β-半乳糖苷酶处理去蛋白质的乳材料的步骤,以便生产包含β-半乳-寡糖(GOS)的乳材料。因此,在乳材料浓缩(步骤(a))之前和/或乳糖去除步骤(步骤(b))之后可用β-半乳糖苷酶对乳材料进行处理,但是优选地发生在乳糖去除步骤完成之后。β-半乳糖苷酶催化乳糖分解为单糖半乳糖和葡萄糖,且随后形成半乳-寡糖。优选地,所用的β-半乳糖苷酶来源于米曲霉。此种酶是作为LactaseF可通过商业途径从Amano,日本获得的。根据FCCIV方法所测定的酶活性可为1000至30000U/kg乳糖之间。原料的酶处理可在3-8的pH范围内,4-70℃的温度下,乳糖浓度为5-70g/100gTS之间,酶浓度为1.5-10g每kg寡糖混合物。优选地,大约酶kg寡糖混合物使用约5g酶,在40-70℃下孵育1至24小时。酶可在使用后通过加热来灭活。
优选地,乳糖去除步骤可通过乳糖结晶来实现。在浓缩的原料中通过例如在加入或不加入晶种时冷却浓缩的材料可实现乳糖结晶。然后将乳糖晶体通过任一已知的方法,例如通过离心、过滤、倾析除去。
从寡糖中分离乳糖的备选方法使用差别溶解度。将原料喷雾干燥,然后加水溶解寡糖,同时使寡糖处于结晶形式。
所获得的液体高度富含寡糖,寡糖:乳糖的比例与该液体所来源的乳中所发现的比例相比高2至200倍。
可如上所述对液体进行再浓缩,并可进行进一步的乳糖去除步骤。此方法可根据需要进行重复。
当除去所期望量的乳糖时,可用单独的蛋白酶和/或其组合来处理液体,以将任何残留的乳蛋白质和肽降解为分子量减小的实体。如果有意将该混合物掺入低变应原性婴儿配方中,此步骤是所希望的。
优选地,该液体也如上所述用β-半乳糖苷酶处理以形成β-半乳-寡糖。这样获得了第二种用于食品的建议成分,所述食品包含如上所述的乳寡糖和具有3-10的DP的GOS。
当用1-6mgβ-半乳糖苷酶每gTS处理具有50%的总固体浓度和大约35%乳糖的液体时,所获得的溶液可含有大约2-4%寡糖、大约2-15%GOS、大约15-30%乳糖、大约5-10%半乳糖和大约2-14%葡萄糖。寡糖:β-GOS的比例可在0.01至99的范围内,但在1.2至1:20,优选地1:2至1:6的范围内。
所获得的液体可以液体形式使用或者可进行干燥(例如通过喷雾干燥)以形成粉末。所获得的粉末含有大约50%乳糖,剩余物是寡糖(大约1-20%,包括唾液酸化寡糖)、单糖例如葡萄糖和半乳糖、大约10%非蛋白质的含氮化合物、2%剩余蛋白和一些剩余盐的混合物。
在本发明优选的方面,将如上所述的寡糖混合物掺入食品中。在本发明的上下文中,术语“食品”意为包含任何可消费的物质。因此,其可为有意供给人类消费的产品,特别是婴儿配方、脱水奶粉,包括成长奶粉或谷类混合物。
婴儿配方可通过任何合适的方式来制备。例如,可通过将蛋白质源、除乳糖之外的任何糖类和脂肪源以合适的比例混和在一起来制备婴儿配方。如果需要的话可加入乳化剂。此时可加入维生素和矿物质,但通常随后再加入以避免热降解。任何亲脂维生素、乳化剂等可在混和之前溶解于脂肪源中。水,优选地已进行反向透析的水,可随后混和进去以形成液体混合物。
然后可将液体混合物加热处理以减少细菌负载量。例如,可将液体混合物快速加热至大约80℃至大约110℃范围的温度大约5秒钟至大约5分钟。这可通过蒸汽注射或通过热交换器例如板式热交换器来完成。
然后将液体混合物冷却至大约60℃至大约85℃,例如通过瞬时冷却。然后将液体混合物搅匀,例如以两个步骤进行,在第一步中在大约7MPa至大约40MPa下,第二步中在大约2MPa至大约14MPa下。然后进一步冷却搅匀的混合物,以便加入热敏感成分例如维生素和矿物质。此时方便地对搅匀的混合物的pH和固体含量进行标准化。
将搅匀的混合物转移至合适的干燥设备中,例如喷雾干燥器或冷冻干燥器中,并将其转变为粉末。该粉末应当具有以重量计少于约5%的含湿量。
可在制造过程中的合适阶段通过湿混和或者通过干混和将本发明的寡糖混合物加入婴儿配方或其它食品中,但优选地在喷雾干燥前立即通过湿混和加入,例如在标准罐中。然而,对于本领域的技术人员,这一点是明显的,即婴儿配方中糖类的量需要进行调整以便考虑寡糖混合物将要提供的另外的糖类。小孩或婴儿食品或配方中寡糖混合物的终浓度优选地在2至50g/l之间,例如作为消费的配方中的32.5g/l。然而,这些量不应视为限制性的,且应根据目标人群进行调整,例如基于小孩或婴儿的体重和年龄或健康进行调整。优选地,每次喂养时给小孩喂养含有本发明寡糖混合物的配方。
备选地,可通过干混和将寡糖混合物加入婴儿或成人食品中。该混合物可以约5至40克寡糖每100g干配方的浓度加入小孩或婴儿配方中,不会向配方中引入非天然的高含量乳糖。然而,这些量不应视为限制性的,并应根据目标人群进行适当调整,例如基于小孩或婴儿的体重和年龄、或者特定人群的健康进行调整。
尽管补充特别针对婴儿或小孩营养的食品是优选的,但补充非特别针对的或者针对成人人群的食品可以是有益的。例如,可将本发明的寡糖混合物掺入健康护理营养品和老年人营养品中。此类食品可包括奶、酸乳酪、凝乳、干酪、发酵奶、基于奶的发酵产品、冰淇淋、基于发酵谷类的产品或基于奶的产品等等。
现在将通过参考下列实施例对本发明进行进一步描述。
实施例1
下面描述了一种制备根据本发明的寡糖混合物的方法。
将200,000升乳清超滤渗透物预浓缩至22%(w/w)总固体(TS),在大约75℃巴氏消毒30秒,然后通过在60℃蒸发浓缩以达到59%(w/w)的TS。在结晶器中以每小时2℃的速度将液体冷却24小时至结晶出乳糖。洗涤结晶的乳糖,然后通过绞拧机将其除去。剩余的液体通过倾析器进行澄清。将从澄清器获得的17.7%TS的77000升通过60℃蒸发进行再浓缩以达到55%(w/w)的TS,并将其进行与前面相同条件下的第二次乳糖结晶步骤。将因此所获得的20.5%TS的29000升液体通过电渗析和离子交换的组合以本身已知的方式进行脱矿质,获得28500升90%脱矿质的17.3%TS的液体。此液体含有每100gTS大约2克动物乳寡糖和每100gTS70克乳糖,可通过向湿相中添加而直接加入食品例如婴儿配方中,也可干燥,例如通过喷雾干燥并通过干混和加入食品例如婴儿配方中。
实施例2
将根据实施例1所生产的100kg50%TS的寡糖混合物在标准罐中加热至60℃,并将pH调整至6至6.5。测定混合物中乳糖、葡萄糖、半乳糖、半乳寡糖和其它寡糖的浓度。每克TS中加入4.5mgLactaseF(Amano,日本)并将混合物在60℃下保持3小时。然后通过直接蒸汽注射将温度升至110℃11秒,使酶失活。再次测定混合物中乳糖、葡萄糖、半乳糖、半乳寡糖和其它寡糖的浓度并将结果显示如下。
(%干物质) | 乳糖 | 葡萄糖 | 半乳糖 | OS | GOS |
时间0 | 70 | 3 | 5 | 2 | 0.7 |
3小时后 | 29 | 12 | 11 | 2 | 10 |
实施例3
如下给出了含有根据本发明的寡糖混合物的婴儿配方组合物的实施例。
营养物 | 每100kcal | 每升 |
能量(kcal) | 100 | 670 |
蛋白质(g) | 1.83 | 12.3 |
脂肪(g) | 5.3 | 35.7 |
亚油酸(g) | 0.79 | 5.3 |
α-亚麻酸(mg) | 101 | 675 |
乳糖(g) | 11.2 | 74.7 |
OS混合物(来自实施例1)(g) | 1.49 | 1.0 |
GOS(来自实施例2)(g) | 0.746 | 5.0 |
矿物质(g) | 0.37 | 2.5 |
Na(mg) | 23 | 150 |
K(mg) | 89 | 590 |
Cl(mg) | 64 | 430 |
Ca(mg) | 62 | 410 |
P(mg) | 31 | 210 |
Mg(mg) | 7 | 50 |
Mn(μg) | 8 | 50 |
Se(μg) | 2 | 13 |
维生素A(μg RE) | 105 | 700 |
维生素D(μg) | 1.5 | 10 |
维生素E(mg TE) | 0.8 | 5.4 |
维生素K1(μg) | 8 | 54 |
维生素C(mg) | 10 | 67 |
维生素B1(mg) | 0.07 | 0.47 |
维生素B2(mg) | 0.15 | 1.0 |
烟酸(mg) | 1 | 6.7 |
维生素B6(mg) | 0.075 | 0.50 |
叶酸(μg) | 9 | 60 |
泛酸(mg) | 0.45 | 3 |
维生素B12(μg) | 0.3 | 2 |
生物素(μg) | 2.2 | 15 |
胆碱(mg) | 10 | 67 |
Fe(mg) | 1.2 | 8 |
I(μg) | 15 | 100 |
Cu(mg) | 0.06 | 0.4 |
Zn(mg) | 0.75 | 5 |
Claims (14)
1.来源于动物乳的寡糖混合物,由包括下述步骤的方法处理得到,
(a)将去蛋白质的乳材料浓缩至50-75%总固体;
(b)将浓缩的乳材料进行乳糖去除步骤,以产生具有小于250的乳糖:寡糖比例的液体;以及
(c)将乳材料脱矿质,脱矿质步骤在浓缩步骤之前或在乳糖去除步骤之后进行;
经上述方法处理得到的寡糖混合物具有小于250的乳糖:寡糖比例,且含有与其所来源的乳相同的寡糖谱,经由上述处理的寡糖混合物进一步用β-半乳糖苷酶处理以生产包含β-半乳-寡糖的乳清材料,并且其中寡糖:β-半乳-寡糖比例为1∶2至1∶20之间。
2.如权利要求1所述的寡糖混合物,其中混合物具有125至1.25的乳糖:寡糖比例。
3.如前述权利要求中任意一项的寡糖混合物,其来源于奶牛奶、山羊奶或水牛奶的一种或多种。
4.食品,其包含如前述权利要求中任意一项所述的寡糖混合物。
5.如权利要求4所述的食品,其为婴儿食品或配方。
6.生产寡糖混合物的方法,寡糖混合物来源于动物乳,该方法包括下述步骤:
(a)将去蛋白质的乳材料浓缩至50-75%总固体;
(b)将浓缩的乳材料进行乳糖去除步骤,包括乳糖结晶步骤,及浓缩步骤以去除乳糖晶体,以产生具有小于250的乳糖:寡糖比例的液体;
(c)将乳材料脱矿质,脱矿质步骤在浓缩步骤之前或在乳糖去除步骤之后进行,
经由上述处理获得的寡糖混合物具有与其所来源的乳相同的寡糖谱,
该方法进一步包括用β-半乳糖苷酶处理经上述步骤处理后的乳材料以产生包含β-半乳糖-寡糖的乳清材料。
7.生产寡糖混合物的方法,寡糖混合物来源于动物乳,该方法包括下述步骤:
(a)将去蛋白质的乳材料浓缩至50-75%总固体;
(b)将浓缩的乳材料进行乳糖去除步骤,包括将去蛋白质的乳材料喷雾干燥,且然后加水溶解寡糖,而使乳糖处于结晶形式,以产生具有小于250的乳糖:寡糖比例的液体;以及
(c)将乳材料脱矿质,脱矿质步骤在浓缩步骤之前或在乳糖去除步骤之后进行,
经由上述处理获得的寡糖混合物具有与其所来源的乳相同的寡糖谱,
该方法进一步包括用β-半乳糖苷酶处理经上述步骤处理后的乳材料以产生包含β-半乳糖-寡糖的乳清材料。
8.生产寡糖混合物的方法,所述寡糖混合物来源于动物乳,该方法包括下述步骤:
(a)将去蛋白质的乳材料浓缩至50-75%总固体;
(b)将浓缩的乳材料进行乳糖去除步骤,包括乳糖结晶步骤,及浓缩步骤以去除乳糖晶体,以产生具有小于250的乳糖:寡糖比例的液体;和
(c)将乳材料脱矿质,脱矿质步骤在浓缩步骤之前或在乳糖去除步骤之后进行,
经由上述处理获得的寡糖混合物具有与其所来源的乳相同的寡糖谱,
该方法进一步包括用β-半乳糖苷酶处理经上述步骤处理后的液体产物以产生包含β-半乳糖-寡糖的液体。
9.生产寡糖混合物的方法,所述寡糖混合物来源于动物乳,该方法包括下述步骤:
(a)将去蛋白质的乳材料浓缩至50-75%总固体;
(b)将浓缩的乳材料进行乳糖去除步骤,包括将去蛋白质的乳材料喷雾干燥,且然后加水溶解寡糖,而使乳糖处于结晶形式,以产生具有小于250的乳糖:寡糖比例的液体;以及
(c)将乳材料脱矿质,脱矿质步骤在浓缩步骤之前或在乳糖去除步骤之后进行,
经由上述处理获得的寡糖混合物具有与其所来源的乳相同的寡糖谱,
该方法进一步包括用β-半乳糖苷酶处理经上述步骤处理后的液体产物以产生包含β-半乳糖-寡糖的液体。
10.如权利要求6至9任一项所述的方法,其中所使用的β-半乳糖苷酶来源于米曲霉。
11.如权利要求6至10中任意一项所述的方法,其中去蛋白质的乳材料是乳超滤渗透物或乳清超滤渗透物。
12.如权利要求6至11中任意一项所述的方法,其中将乳糖去除步骤重复一次或多次,以进一步浓缩液体和去除乳糖。
13.如权利要求6至12中任意一项所述的方法,其还包括用单独的蛋白酶和/或其组合处理液体产物,以便将任何残留的乳蛋白质和肽降解为具有减小的分子量的实体。
14.如权利要求6至13任意一项所述的方法,其还包括将液体产物喷雾干燥得到粉末。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05075420.9 | 2005-02-21 | ||
EP05075420 | 2005-02-21 | ||
PCT/EP2006/060130 WO2006087391A1 (en) | 2005-02-21 | 2006-02-21 | Oligosaccharide mixture |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101123888A CN101123888A (zh) | 2008-02-13 |
CN101123888B true CN101123888B (zh) | 2016-03-23 |
Family
ID=34938065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200680005467.9A Active CN101123888B (zh) | 2005-02-21 | 2006-02-21 | 寡糖混合物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8591981B2 (zh) |
EP (1) | EP1926394B1 (zh) |
CN (1) | CN101123888B (zh) |
AU (2) | AU2006215603A1 (zh) |
BR (1) | BRPI0607633A2 (zh) |
CA (1) | CA2601917C (zh) |
ES (1) | ES2781328T3 (zh) |
MX (1) | MX2007010094A (zh) |
PT (1) | PT1926394T (zh) |
RU (1) | RU2442438C2 (zh) |
WO (1) | WO2006087391A1 (zh) |
ZA (1) | ZA200708100B (zh) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006012536A2 (en) | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
RU2442438C2 (ru) | 2005-02-21 | 2012-02-20 | Нестек С.А. | Смесь олигосахаридов |
EP1776877A1 (en) | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
WO2007051475A1 (en) | 2005-11-04 | 2007-05-10 | Arla Foods Amba | A concentrate derived from a milk product enriched in naturally occurring sialyllactose and a process for preparation thereof |
WO2007090894A1 (en) † | 2006-02-10 | 2007-08-16 | Nestec S.A. | Oligosaccharide mixture |
US9005682B2 (en) * | 2006-03-07 | 2015-04-14 | Nestec S.A. | Synbiotic mixture |
EP2157870A1 (en) * | 2007-06-25 | 2010-03-03 | DSM IP Assets B.V. | Novel prebiotics |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
EP2143341A1 (en) | 2008-07-08 | 2010-01-13 | Nestec S.A. | Nutritional Composition Containing Oligosaccharide Mixture |
WO2009151315A1 (en) * | 2008-06-13 | 2009-12-17 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
US20110117077A1 (en) * | 2008-06-13 | 2011-05-19 | N.V. Nutricia | Nutritional composition for infants delivered via caesarean section |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
KR20170053733A (ko) | 2009-02-24 | 2017-05-16 | 리터 파마슈티컬즈 인코오포레이티드 | 프리바이오틱 제제 및 사용 방법 |
WO2010107506A1 (en) * | 2009-03-20 | 2010-09-23 | Milk Specialties Company | Non-setting hydroluzed whey permeate concentrate and related methods and nutritional compositions |
ES2433429T3 (es) | 2009-07-15 | 2013-12-11 | N.V. Nutricia | Mezcla de oligosacáridos no digeribles para estimular el sistema inmunológico |
BR112012000859B1 (pt) * | 2009-07-15 | 2021-08-03 | N.V. Nutricia | Uso de 2'-fucosilactose na fabricação de uma composição enteral |
IT1395068B1 (it) | 2009-08-07 | 2012-09-05 | Inalco Spa | Processo per la produzione di galatto-oligosaccaridi ultrapuri |
JP5641598B2 (ja) * | 2009-09-29 | 2014-12-17 | 雪印メグミルク株式会社 | シアリルラクトース素材の分離方法 |
WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
EP2455387A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
EP2454948A1 (en) | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
SG190887A1 (en) | 2010-12-21 | 2013-07-31 | Nestec Sa | Container and pouch |
US8795746B2 (en) | 2011-02-16 | 2014-08-05 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic use of mucin glycans |
DK2707380T3 (da) * | 2011-05-13 | 2020-10-12 | Glycom As | DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF |
EP2526784A1 (en) * | 2011-05-24 | 2012-11-28 | Nestec S.A. | Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition |
DE202013012827U1 (de) * | 2012-06-14 | 2020-02-13 | Glycom A/S | Verbesserung der Stabilität und Reinheit sowie Erhöhung der Bioverfügbarkeit von menschlichen Milch-Oligosacchariden oder Vorläufern oder Mischungen davon |
WO2013187755A1 (en) | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
JP6367914B2 (ja) | 2013-03-28 | 2018-08-01 | ネステク ソシエテ アノニム | 体重増加予防のためのプレバイオティクス効力のバイオマーカーとしてのトリメチルアミン |
PL2999358T3 (pl) * | 2013-05-22 | 2021-12-20 | Glycom A/S | Syntetyczna mieszanina oligosacharydów do leczenia mikrobioty ssaka |
US20140348979A1 (en) * | 2013-05-24 | 2014-11-27 | General Mills, Inc. | Soluble fiber from yogurt whey |
US11116235B2 (en) | 2013-05-24 | 2021-09-14 | General Mills, Inc. | Food products with yogurt whey |
US20160192688A1 (en) * | 2013-08-15 | 2016-07-07 | General Mills, Inc. | Soluble Fiber from Yogurt Whey |
RU2687038C1 (ru) | 2013-11-29 | 2019-05-06 | Нестек С.А. | Соответствующие возрастным потребностям питательные композиции с различным содержанием белка |
AU2013406461A1 (en) | 2013-11-29 | 2016-05-05 | Nestec S.A | Liquid milk fortifier composition with relatively high lipid content |
ES2942850T3 (es) | 2015-06-01 | 2023-06-07 | Saisei Pharma Co Ltd | Producto lácteo tratado con enzimas, procedimiento para producirlo, composición y producto |
GB201518007D0 (en) * | 2015-10-12 | 2015-11-25 | Promovita Ingredients Ltd | Manufacture of polymeric sugars |
EP3407893A1 (en) | 2016-01-26 | 2018-12-05 | Nestec S.A. | Human milk oligosaccharides against later in life excessive fat mass accumulation and related health disorders |
WO2017129644A1 (en) | 2016-01-26 | 2017-08-03 | Nestec S.A. | Compositions with specific oligosaccharides to prevent or treat allergies |
US20180007937A1 (en) * | 2016-07-11 | 2018-01-11 | Proliant Dairy, Inc. | Process for making galacto-oligosaccharide product |
SG11201811807XA (en) | 2016-07-28 | 2019-02-27 | Fonterra Cooperative Group Ltd | Dairy product and process |
AU2017307952A1 (en) | 2016-08-04 | 2018-11-29 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally Bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea |
MX2019004583A (es) | 2016-11-10 | 2019-08-12 | Soc Des Produits Nestle S A Star | Composicion en forma de polvo que comprende hierro y bacterias probioticas. |
WO2018109063A1 (en) | 2016-12-15 | 2018-06-21 | Nestec S.A. | Composition in powder form comprising iron-milk protein complexes and probiotic bacteria |
WO2018109079A1 (en) | 2016-12-15 | 2018-06-21 | Nestec S.A. | Composition in powder form comprising iron-casein complexes and compounds sensitive to oxidation |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
EP3731658A1 (en) | 2017-12-28 | 2020-11-04 | Société des Produits Nestlé S.A. | Composition comprising ferrous sulphate monohydrate and long chain polyunsaturated fatty acids |
AU2019409827A1 (en) | 2018-12-19 | 2021-05-27 | Société des Produits Nestlé S.A. | Composition for preventing or reducing transepidermal water loss and improving skin barrier function |
CN113226063A (zh) * | 2019-01-02 | 2021-08-06 | 菲仕兰坎皮纳荷兰公司 | 用来自土生隐球菌的β-半乳糖苷酶制备GOS制剂的方法、由此获得的GOS制剂及其用途 |
CA3203492A1 (en) | 2021-01-04 | 2022-07-07 | Cameron Marshall | Demineralised lactose concentrate |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2584158A (en) | 1950-01-10 | 1952-02-05 | Wyeth Corp | Recovery of lactose from mother liquor |
US4202909A (en) | 1976-11-22 | 1980-05-13 | Patent Technology, Inc. | Treatment of whey |
JPS58190388A (ja) | 1982-04-30 | 1983-11-07 | Yakult Honsha Co Ltd | ビフイドバクテリウム菌の増殖促進物質の製造法 |
FI864637A (fi) | 1986-06-04 | 1987-12-05 | Dairy Technology Ltd | Framstaellning av laktos i ett steg. |
JPS63109789A (ja) * | 1986-10-27 | 1988-05-14 | Yakult Honsha Co Ltd | オリゴ糖の製造法 |
FI78504C (fi) * | 1987-10-14 | 1989-08-10 | Valio Meijerien | Foerfarande foer tillvaratagande av laktos ur vassla. |
JPH0710875B2 (ja) | 1989-03-10 | 1995-02-08 | 雪印乳業株式会社 | シアル酸類含有脱塩乳糖の製造方法 |
JPH03216185A (ja) | 1990-01-17 | 1991-09-24 | Unitika Ltd | ビフイドバクテリウム菌増殖促進剤の製造方法 |
JP2930370B2 (ja) | 1990-05-25 | 1999-08-03 | 雪印乳業株式会社 | ガラクトオリゴ糖類含有脱脂粉乳の製造方法 |
JP3035833B2 (ja) | 1991-01-21 | 2000-04-24 | 雪印乳業株式会社 | シアル酸類含有組成物の製造方法 |
US5882714A (en) * | 1996-04-15 | 1999-03-16 | The Iams Company | Queens milk replacer |
US5792501A (en) * | 1996-04-15 | 1998-08-11 | The Iams Company | Queen's milk replacer |
JP4592126B2 (ja) * | 1999-02-24 | 2010-12-01 | 雪印乳業株式会社 | ミルクミネラル組成物 |
DE19958985A1 (de) * | 1999-12-07 | 2001-06-13 | Nutricia Nv | Oligosaccharidmischung |
US6288222B1 (en) * | 2000-02-16 | 2001-09-11 | Neose Technologies, Inc. | Method of filtration of a dairy stream |
JP2001240599A (ja) | 2000-02-29 | 2001-09-04 | Snow Brand Milk Prod Co Ltd | 乳由来オリゴ糖画分 |
US20020102329A1 (en) | 2000-07-22 | 2002-08-01 | Michael Lanahan | Methods for high-temperature hydrolysis of galactose-containing oligosaccharides in complex mixtures |
AUPR217700A0 (en) | 2000-12-19 | 2001-01-25 | Food Science Australia | Methods for purification of lactose |
FR2838452B1 (fr) | 2002-04-10 | 2004-07-09 | Eurodia Ind | Procede de production en continu de galacto oligosaccharides |
NZ523100A (en) | 2002-12-10 | 2005-02-25 | Fonterra Co Operative Group | A process for producing a carbohydrate composition |
GB0229015D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
RU2442438C2 (ru) | 2005-02-21 | 2012-02-20 | Нестек С.А. | Смесь олигосахаридов |
-
2006
- 2006-02-21 RU RU2007135017/10A patent/RU2442438C2/ru active
- 2006-02-21 MX MX2007010094A patent/MX2007010094A/es active IP Right Grant
- 2006-02-21 EP EP06708410.3A patent/EP1926394B1/en active Active
- 2006-02-21 ES ES06708410T patent/ES2781328T3/es active Active
- 2006-02-21 WO PCT/EP2006/060130 patent/WO2006087391A1/en active Application Filing
- 2006-02-21 AU AU2006215603A patent/AU2006215603A1/en not_active Abandoned
- 2006-02-21 BR BRPI0607633-5A patent/BRPI0607633A2/pt not_active Application Discontinuation
- 2006-02-21 US US11/816,516 patent/US8591981B2/en active Active
- 2006-02-21 CA CA2601917A patent/CA2601917C/en not_active Expired - Fee Related
- 2006-02-21 CN CN200680005467.9A patent/CN101123888B/zh active Active
- 2006-02-21 PT PT67084103T patent/PT1926394T/pt unknown
-
2007
- 2007-09-20 ZA ZA200708100A patent/ZA200708100B/xx unknown
-
2012
- 2012-06-19 AU AU2012203568A patent/AU2012203568C1/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2012203568B2 (en) | 2015-02-19 |
AU2012203568A1 (en) | 2012-07-12 |
EP1926394B1 (en) | 2020-02-19 |
MX2007010094A (es) | 2007-09-25 |
CN101123888A (zh) | 2008-02-13 |
AU2012203568C1 (en) | 2017-11-02 |
CA2601917A1 (en) | 2006-08-24 |
RU2007135017A (ru) | 2009-03-27 |
PT1926394T (pt) | 2020-05-22 |
ES2781328T3 (es) | 2020-09-01 |
US8591981B2 (en) | 2013-11-26 |
RU2442438C2 (ru) | 2012-02-20 |
US20090035813A1 (en) | 2009-02-05 |
WO2006087391A1 (en) | 2006-08-24 |
CA2601917C (en) | 2013-12-10 |
BRPI0607633A2 (pt) | 2009-09-22 |
AU2006215603A1 (en) | 2006-08-24 |
ZA200708100B (en) | 2009-09-30 |
EP1926394A1 (en) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101123888B (zh) | 寡糖混合物 | |
AU2007213677B2 (en) | Oligosaccharide mixture | |
AU2012260945B2 (en) | Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition | |
CN103797021B (zh) | 寡糖混合物以及包含该混合物的食品,特别是婴儿配方产品 | |
WO2008037839A1 (en) | Method for producing products containing galactooligosaccharides and use thereof | |
US20140314935A1 (en) | Fermented flavoring system derived from greek yogurt processing | |
WO2016168853A1 (en) | Method for making a fermented whey protein product | |
Önür et al. | 4. INNOVATIVE PRODUCTS PRODUCED FROM WHEY | |
JP3789146B2 (ja) | オリゴ糖含有栄養組成物 | |
Casarotti et al. | Fermented Dairy Beverages in Latin America | |
MX2008010261A (en) | Oligosaccharide mixture | |
RO130656B1 (ro) | Produs alimentar prebiotic, pe bază de zer dulce integral, şi procedeu de obţinere |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190729 Address after: Vevey Patentee after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Patentee before: Nestec SA |
|
TR01 | Transfer of patent right |